This research program (GM-41821), now in its seventh year, embodies our long-term commitment to the design and synthesis on non-peptide peptidominetics. The principal goals for years 8 through 11 are: (A) In the SRIF receptor project we will continue to optimize the sugar scaffold and the side chains, to produce ligands with both nanomolar and subnanomolar affinities especially for the receptor subtype 2 (SSTR 2) and good pharmacokinetic properties. These efforts will build on advances with: (1) mannose-based immidazole sugars; (2) desindole sugars; (3) unsaturated lysine-containing sugars; and further explore (4) modifications of the indole side chain; and (5) incorporation of fromamidines. In addition, we will: (6) seek to understand the factors responsible for SSTR specificity; and (7) continue to test for SRIF antagonism. (B) In our NK-1 receptor program we will: (1) define the binding mode of sugar-based ligands to the NK-1 receptor; (2) use the c-hexapeptide 17 to design a sugar ligand; (3) improve the solubility of our mimetics by introducing glucosamine-based sugars and replacing benzyl side-chains with pyridyl analogs; (4) employ 17 as a template for conversion of the tetradecapeptide hormone somatostatin (SRIF) into an NK-1 receptor. (C) To close the loop between the peptide and non-peptide ligands for G-protein-coupled receptors, will return to the beta2-adrenergic receptor and: (1) attempt to design the first peptidal ligand by mimicking the structures of our polyvalent sugars; (2) use the latter results to optimize the sugar lead; and (3) test these compounds for Beta 3-adrenergic receptor affinity. (D) Exploiting the fact that the cyclic hexapeptide scaffold represents a privileged platform, we will also: (1) optimize the first non-amine-containing peptidal morphine receptor ligands, which we discovered; and (2) design an opiate sugar, once again based upon the corresponding peptide data. (E) As one approach to increasing diversity, we propose to construct novel privileged platforms by preparing chimeric sugars integrated into: (1) the benzodiazepine framework and (2) the so-called tricyclic platform. We will submit the resulting compounds to broad-based receptor screening at DuPont Merck, Merck Research Laboratories, and possibly elsewhere. (F) Because our sugars represent a new class of privileged platforms, we will generate small libraries of monosaccharides via parallel solid-phase synthesis (SPS).

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
Schools of Arts and Sciences
United States
Zip Code
Smith 3rd, Amos B; Charnley, Adam K; Hirschmann, Ralph (2011) Pyrrolinone-based peptidomimetics. ""Let the enzyme or receptor be the judge"". Acc Chem Res 44:180-93
Hirschmann, Ralph F; Nicolaou, K C; Angeles, Angie R et al. (2009) The beta-D-glucose scaffold as a beta-turn mimetic. Acc Chem Res 42:1511-20
Foister, Shane; Taylor, Laurie L; Feng, Jin-Jye et al. (2006) Design and synthesis of potent cystine-free cyclic hexapeptide agonists at the human urotensin receptor. Org Lett 8:1799-802
Mowery, Brendan P; Prasad, Vidya; Kenesky, Craig S et al. (2006) Catechol: A minimal scaffold for non-peptide peptidomimetics of the i + 1 and i + 2 positions of the beta-turn of somatostatin. Org Lett 8:4397-400
Angeles, Angie R; Neagu, Irina; Birzin, Elizabeth T et al. (2005) Synthesis and binding affinities of novel SRIF-mimicking beta-D-glucosides satisfying the requirement for a pi-cloud at C1. Org Lett 7:1121-4
Neelamkavil, S; Mowery, B P; Thornton, E R et al. (2005) A practical synthesis of Nalpha-Fmoc-L-pyrazinylalanine via Schollkopf's chiral auxiliary. J Pept Res 65:139-42
Neelamkavil, Santhosh; Arison, Byron; Birzin, Elizabeth et al. (2005) Replacement of Phe6, Phe7, and Phe11 of D-Trp8-somatostatin-14 with L-pyrazinylalanine. Predicted and observed effects on binding affinities at hSST2 and hSST4. An unexpected effect of the chirality of Trp8 on NMR spectra in methanol. J Med Chem 48:4025-30
Abrous, Leila; Jokiel, Patrick A; Friedrich, Sarah R et al. (2004) Novel chimeric scaffolds to extend the exploration of receptor space: hybrid beta-D-glucose-benzoheterodiazepine structures for broad screening. Effect of amide alkylation on the course of cyclization reactions. J Org Chem 69:280-302
Prasad, Vidya; Birzin, Elizabeth T; McVaugh, Cheryl T et al. (2003) Effects of heterocyclic aromatic substituents on binding affinities at two distinct sites of somatostatin receptors. Correlation with the electrostatic potential of the substituents. J Med Chem 46:1858-69
Smith 3rd, Amos B; Cantin, Louis-David; Pasternak, Alexander et al. (2003) Design, synthesis, and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors. J Med Chem 46:1831-44

Showing the most recent 10 out of 26 publications